Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct information

Dosage forms and strengths

2 evidence topics · 3 sources

Route of administration and preparation in clinical trials

“Patients received an intravenous infusion of ABL001/CTX‐009 diluted in 0.9% normal saline (250 mL) over 1 h.” (opens the source at this quote in a new tab)

FieldQuoted record
Intervention type“Drug”
Intervention name“CTX-009”
Intervention description“IV infusion on day 1 and 14 of every 28 day cycle”
Dose units used in clinical trials

“CTX-009 will be administered at 10 mg/kg on Day 1 and Day 15 of every 28-day cycle.” (opens the source at this quote in a new tab)

“Nine dose levels were tested in the phase I monotherapy study, at doses ranging from 0.3 to 17.5 mg/kg biweekly.” (opens the source at this quote in a new tab)

Commercial formulation, vial strength, and storage

No evidence found.